Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

[EX Q]: The Battle of al-Qadisiyyah (Arabic: ; transliteration, Ma'rakatu al-Qadisiyyah; Persian: transliteration Nabard-e Qadesiyeh; alternative spellings: Qadisiyya, Qadisiyyah, Kadisiya, Ghadesiyeh), fought in 636, is said to be a decisive engagement between the Arab Muslim army and the Sassanid Persian army during the first period of Muslim expansion.
[EX A]: On what date did Battle of al-Qādisiyyah end?

[EX Q]: Bimberamala River, a perennial river of the Clyde River catchment, is located in the Southern Tablelands and the upper ranges of the South Coast regions of New South Wales, Australia.
[EX A]: What body of water does Bimberamala River join?

[EX Q]: Bone pain is a common symptom in bone metastases. The therapies that are currently available include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, steroids and gabapentin which have been demonstrated to improve neuropathic pain. In addition, preclinical studies indicate that agents such as transient receptor potential vanilloid 1 antagonists and cannabinoid 2 receptor agonist could be considered as adjuncts in ameliorating opioid side effects. New drugs are in the clinical phase of development, among which the most promising molecules seem to be anti-nerve growth factor (NGF) antibodies. Anti-NGF antibody therapy may be particularly effective in blocking bone cancer pain because NGF appears to be integrally involved in the upregulation, sensitization and disinhibition of multiple neurotransmitters, ion channels and receptors in the primary afferent nerve. The best way to treat bone metastases pain is to improve the control of skeletal disease burden. Recently, denosumab, a noncytotoxic IgG2 monoclonal antibody with high affinity for human RANKL, has been demonstrated to significantly prevent clinically relevant increase in pain compared with zoledronic acid across the tumor types. Based on these data, it has been suggested that denosumab has the potential to become a new standard of treatment in bone metastases management.
[EX A]:
To the ligand of which receptors does Denosumab (Prolia) bind?